Marc Hainaut

Marc Hainaut


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
LDLorraine Dethioux
Lorraine Dethioux
NDNicolas Dauby
Nicolas Dauby
IMIsabel Montesinos
Isabel Montesinos
ERElisabeth Rebuffat
Elisabeth Rebuffat
MHMarc Hainaut
Marc Hainaut

29 September 2023 in Viruses
Verified
Journal Article
Open access
PDF file
IDInès Dufour
Inès Dufour
YFYves Fougère
Yves Fougère
TGTessa Goetghebuer
Tessa Goetghebuer
MHMarc Hainaut
Marc Hainaut
BMBenoît Mukinayi MBIYA
Benoît Mukinayi MBIYA
DLDimitri Van der Linden
Dimitri Van der Linden
The management of adolescents living with HIV represents a particular challenge in the global response to HIV. The challenges specific to this age group include difficulties engaging and maintaining them in care, challenges with transition to adult care, and limited therapeutic options for treatment-experienced patients, all of which have been jeopardized by the COVID-19 pandemic. This paper summarizes some of the challenges in managing adolescents living with HIV, as well as some of the most recent and innovative therapeutic approaches in this population.

11 November 2021 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
VKValbona Selimaj Kontoni
Valbona Selimaj Kontoni
PLPhilippe Lepage
Philippe Lepage
MHMarc Hainaut
Marc Hainaut
VDVéronique Yvette Miendje Deyi
Véronique Yvette Miendje Deyi
WMWesley Mattheus
Wesley Mattheus
DPDavid Pace
David Pace

16 May 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MDMilena Demey
Milena Demey
ABArnaud Rn Bruyneel
Arnaud Rn Bruyneel
OCOlga Chatzis
Olga Chatzis
CCChristelle Christiaens
Christelle Christiaens
VCVeerle Cossey
Veerle Cossey
ATAnne Tilmanne
Anne Tilmanne
Our study aimed to assess the severity of severe acute respiratory syndrome coronavirus 2 infection in hospitalized infants under 40 days old, across 21 Belgian hospitals between 2020 and 2022. Of the 365 infants studied, 14.2% needed respiratory support. The median hospital stay was 3 days (interquartile range, 2–4), and there were no deaths. Infection severity was similar during the Omicron and Alpha/Delta periods.

22 October 2026 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
XLXin Liu
Xin Liu
PPPerrin Ngougni Pokem
Perrin Ngougni Pokem
MHMarc Hainaut
Marc Hainaut
CFChristine Ferreiro
Christine Ferreiro
CACatherine Adler
Catherine Adler
FBFrançoise Van Bambeke
Françoise Van Bambeke
Background: Temocillin, active against most extended-spectrum β-lactamases (ESBL)-producing Enterobacterales , is increasingly considered a carbapenem-sparing option for Gram-negative infections. Despite a recommended pediatric dose of 25–50 mg/kg/d in 2 administrations, its pharmacokinetics in children remain ill characterized. This study aimed to characterize temocillin pharmacokinetics in young children with urinary tract infections using population pharmacokinetic modeling and to evaluate target attainment using Monte Carlo simulations. Methods: Eligible patients contributed 1–2 blood samples collected at different time points, providing coverage of the dosing interval through an ethically acceptable sparse sampling strategy. Total and unbound temocillin plasma concentrations were quantified using high-performance liquid chromatography–tandem mass spectrometry, and data were used for pharmacokinetic modeling. Probabilities of target attainment were calculated using Monte Carlo simulation. Results: Pediatric patients (6–34 months) hospitalized with urinary tract infection received temocillin at a dose of 25 mg/kg twice daily. Thirty unbound and 33 total plasma concentrations collected from 30 patients were available for analysis. A 1-compartment structural model including nonlinear protein binding was supported. Population pharmacokinetic estimates fell within the corresponding 95% confidence intervals and were consistent with bootstrap medians, supporting model stability. Clearance and volume of distribution were estimated at 2.81 L/h and 10.3 L, respectively. Interindividual variability of clearance was determined to be 21.2% in the population. Modeling predicted that the studied regimen would provide a >90% probability of target attainment against organisms with minimum inhibitory concentration (MIC) ≤2 mg/L when targeting 40% of the dosing interval with free-drug concentrations above the MIC (40% fT>MIC). Conclusion: Although sparse sampling limits parameter precision, characterization of interindividual variability, and covariate evaluation, these data may serve as an exploratory reference to inform preliminary dosing considerations in this pediatric population.